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Abstract
Background: Cardiovascular disease has a multifactorial aetiology with a number of both modifiable and non-modifiable
risk factors. Although evidence indicates that dietary intake plays an important role, few studies have focused on
the effect of fruit and vegetable consumption on early markers of vascular function. Therefore, we hypothesised
that supplementation with capsules containing a combination of fruit and vegetable extracts over 12 weeks can
significantly modulate biomarkers of vascular function compared with a control group receiving placebo.
Methods/Design: This is a double-blind, randomised controlled trial that includes overweight and obese but
otherwise healthy participants. Participants are randomly allocated to one of two groups: active supplementation
(encapsulated fruit and vegetable powder) or placebo taken twice daily for 12 weeks, whereas both groups will
be given the ‘5-A-Day’ dietary advice. The primary outcome is to measure changes to the carotid intima media
thickness (cIMT) between the two groups from baseline (test visit 1) to 12 weeks later (test visit 2). The secondary
outcomes include macro- and microvascular changes and changes to blood markers.
Discussion: In addition to the primary and secondary objectives, this explanatory trial incorporates potential novel
biomarkers such as trimethylamine-N-oxide (TMAO) and lipopolysaccharide (LPS).
Trial registration: ISRCTN14315618. Registration date 27 February 2014.
Keywords: Vascular function, endothelial function, fruit and vegetable extracts, capsule supplementation, placebo,
carotid intima media thickness, double-blind RCT
Background
Background and rationale
Increasingly, dietary intake and nutrition are recognised as
playing a major role in the aetiology of CVD [1]. A number
of epidemiologic and observational studies regularly report
that consuming fruit and vegetables (F&Vs) can lower
CVD risk. Among several studies that have looked into the
beneficial effects of F&Vs in lowering CVD risk, Yusuf and
colleagues [2] reported that the population attributable risk
for acute myocardial infarction given irregular consump-
tion of F&Vs was 12.9 %. Also, Crowe and colleagues [3]
reported that participants consuming at least 80 g of F&Vs
per day had a 22 % lower risk of fatal ischaemic heart
disease. Berry fruits have also been shown a reduction in
blood pressure as well as a reduction in the levels of pro-
inflammatory markers and adhesion molecules, which are
both markers of endothelial function [4].
Endothelial dysfunction is emerging as a potential set
of early markers of cardiovascular disease risk. It is
considered to play a principal role in the initiation and
progression of atherosclerosis, and it is also present in
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later stages of vascular disease. Many studies have used
a variety of tests in order to measure endothelial
function as well as to assess the impact of potentially
therapeutic interventions on the vasculature [5]. In a
placebo-controlled crossover study, a short fruit extract
intervention study led to improved endothelial vasodila-
tion measured by flow mediated dilatation (FMD) in
individuals at risk for CVD [6].
Evidence suggests that dietary flavonoids work in vari-
ous ways and reduce oxidative stress, which is caused by
factors such as smoking, obesity, hypertension and other
pathological conditions [7]. Specifically, phytonutrients
in F&Vs may have specific cardio-protective effects par-
tially mediated through favourable effects on endothelial
function, inhibition of angiogenesis and cell migration
and proliferation in blood vessels [8]. Although recent
health and public reports focus on the five portions of a
range of F&V as being cardio-protective [9, 10], clear
dose-response relations are poorly defined, which has
resulted in major inconsistencies in F&Vs recommenda-
tions. Overall, the body of evidence is growing on the
modulation of endothelial, as well as macro- and micro-
vascular function (predictive of cardiovascular risk), due
to interventions using different categories of F&Vs or
chronic ingestion of selected phytonutrients. However, a
paucity of studies have examined the vascular modula-
tory effects of chronic unselective exposure to a high
dose of a very wide range of phytonutrients derived from
F&Vs, and it is currently not known whether this can
bring about similar magnitudes and patterns of vascular
change as compared with exposure to selected F&Vs.
We hypothesize that a high dose of unselective phytonu-
trients derived from F&Vs, when ingested chronically,
will result in potentially beneficial changes (compared
with placebo) to both macro- and microvascular mea-
sures, through modulation of endothelial and conduit
function of arteries, thus mitigating cardiovascular risk.
Methods/Design
Aim/Objectives
The aim of this study is to evaluate the effects of supple-
mentation with encapsulated fruit and vegetable powder
compared with placebo on vascular and endothelial func-
tion before and after 12 weeks of intervention when they
are both given with ‘5-A-Day’ dietary advice verbally and
in writing.
Specifically, the primary objective of this trial is to
assess whether there is a change in the carotid intima
media thickness (cIMT) between the two groups.
The secondary objectives are to assess the following:
1. Dynamic macrovascular and microvascular changes.
2. Changes in laboratory blood markers, including
endothelial cell function and oxidative stress.
3. Changes in Knowledge, Attitudes and Practices
(KAP) using the Five-a-day Community Evaluation
Tool (FACET).
4. Changes to safety indicators: liver function, routine
bloods (including full blood count) and ECG.
Study design
This study is a double-blind, randomised controlled trial
for overweight and obese but otherwise healthy partici-
pants. It is being conducted at the Medical Research
Council (MRC), Human Nutrition Research (HNR) unit
in Cambridge, United Kingdom. The study had two stages
of ethical approval; first, an internal research governance
approval was granted by the Research Review Board
(RRB) at MRC HNR, which comprises joint scientific
and ethical peer review. Full independent research eth-
ics approval was subsequently obtained from the NHS
National Research Ethics Service (REC Reference: 13/
EE/0095) and fully informed written consent is taken
from all participants. Confirmation that this study does
not fall under the legal definition of a Clinical Trial of
an Investigational Medicinal Product (CTIMP) was
sought from the Medicines and Healthcare Products
Regulatory Agency (MHRA) Borderline Team.
Participants and setting
Inclusion criteria
Participants are eligible for this study if they fulfil the
following criteria: (1) aged between 25 and 65 years; (2)
BMI 25 to 35 kg/m2; (3) able and willing to take gelatin
casing capsule supplements for 12 weeks and complete
the required evaluations; and (4) competent and willing
to give informed consent.
Exclusion criteria
People with any of the following will be excluded from
participation: (1) all diagnosed cardiovascular risk factors
or disorders; (2) diabetes and disorders of glycaemic con-
trol; (3) irritable and inflammatory bowel disorders and
acid peptic disease; (4) any active tumours/cancers; (5)
lipid or cholesterol lowering tablets; (6) continuous use of
any nutritional supplements and/or prescription medica-
tion likely to impact on study measurements or safety; (7)
pregnancy or breastfeeding; (8) high-dose aspirin and
analogues; (9) high levels of physical activity; (10) current
active mental and/or neurological illness and the use of
related medication; and/or (11) currently smoking.
Sample size
The sample size calculation was performed according
to cIMT changes over 12 weeks of supplementation.
cIMT normal values in the general adult population
(including overweight individuals) less than 65 years of
age, range from 0.60 to 0.80 mm with a SD of 0.10 mm.
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[7]. Assuming a two-tailed t-test using a 5 % significance
level (two-sided), a sample size of 37 in each group (74
participants in total) was determined to have 85 % power
to detect a mean cIMT difference of 0.07 mm after
12 weeks of supplementation between the intervention
and control groups, assuming a common SD of 0.10 mm.
Allowing for a dropout rate of approximately 15 %, we aim
to recruit 80 participants in total; n = 40 in the placebo and
n = 40 in the intervention group.
Randomisation and blinding
When all inclusion criteria have been met and informed
consent has been obtained, participants will be randomly
allocated to one of the two groups. Randomisation is
based on a blocked randomisation sequence generated
by a research statistician independent to the study team
and with the sequence unknown to both researchers and
participants. Two independent code keepers at MRC
HNR, who are not involved in the running of the study,
are securely holding the randomisation code. To main-
tain scientific integrity, at no point will those either gen-
erating or holding the study codes, come into contact
with participants or data analyses. The details of the
allocation are concealed from the research team and the
participants until all data collection and analysis are
complete. Blinding of participants and research team to
allocation status will be assured by identical capsule
appearance and identical labelling between the placebo
and the active supplementation. Blinding of the capsules,
packaging and labelling have been undertaken by the
funding company (National Safety Associates (NSA)
LLC, USA).
Capsule supplementation
Participants are asked to take six 00 capsules daily: three
capsules twice with meals and plenty of water. The inter-
vention supplements were made by blending three sep-
arate formulas. Two of these formulas contain a dried
powder blend of juice and pulp of a number of fruits like
apple, grape and blueberry, whereas the last one consists
of vegetable juice powder and pulp from different vege-
tables such as carrot and broccoli. The total amount of
nutrients contained per six capsules can be found in
Table 1. The placebo capsules contain microcrystalline
cellulose, dicalcium phosphate, magnesium stearate and
FD&C yellow #6.
Study procedures
Recruitment and pre-screening questionnaire
Figure 1 summarises the National Safety Associates
nutritional supplementation trial of fruit and vegetable
extracts and vascular function (NNTV) recruitment and
participant follow-up plan. Table 2 provides an overview
of the study procedures performed at each visit.
Participants are recruited following one of the follow-
ing methods: they are either identified from the MRC
HNR volunteer database and are sent a letter inviting
them to participate in the study, or they respond to a
study advert placed around the community and in local
magazines. Once the volunteer expresses initial interest
in participating in the study, he/she is contacted via tele-
phone by the study coordinator or research assistant.
Both the participant information sheet (PIS), along with
a leaflet describing all the vascular measurements used
in the study, are sent to the potential participant, allow-
ing them at least 24 hours to read and understand the
study aim and procedures and decide if they would like
to take part in the study.
The pre-screening telephone call lasts approximately
15 minutes and follows the structure of a standardised
pre-screening questionnaire. The questionnaire assesses
the potential eligibility of the participant for the study
through a series of questions around the inclusion/ex-
clusion criteria (including medication and self-reported
height and weight) for the study.
Potential participants who are found not to be eligible
will be excluded at this stage. Eligible participants will be
invited to attend the study site (MRC HNR) for a further
screening visit.
Screening visit
Following completion of the pre-screening questionnaire
and provided that the participant is eligible to take part
in the study, he/she is asked to attend the screening
visit, which takes place at HNR and lasts approximately
2 hours.
Informed consent is obtained from all participants
during the screening visit, and any questions relating to
the study are answered, ensuring that the participant has
fully understood all the study procedures before con-
tinuing. Consent is obtained before any measurements
are taken. Height is measured to the nearest 0.1 cm
using a stadiometer, and weight to the nearest 0.1 kg
using calibrated mass scales. BMI is calculated using
these measurements. Two blood pressure readings are
recorded while the patient is in a seated position. A third
BP measurement is performed if the first two readings
have a discrepancy of more than 10 mmHg.




Vitamin E 22 mg
Vitamin C 300 mg
Folate 200 μg
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A full eligibility assessment is carried out using the
HNR volunteer health screening and demographics
questionnaire. Medical history and any recent changes
in medication since the pre-screening questionnaire are
also assessed and evaluated at this stage. In addition,
female participants are also asked about the timing of
their menstrual cycle as this can affect the vascular
measurements in the study. Fasting blood samples are
collected by venepuncture to measure blood lipids, glu-
cose, and liver function as a routine safety measure and
as an indicator of normal metabolism. Table 3 summa-
rises all the blood markers that are examined during the
study. At the end of the visit, the volunteers are asked to
complete two short questionnaires: the International
Physical Activity Questionnaire (IPAQ) and the Five-a-
day Community Evaluation Tool (FACET) and are pro-
vided with ‘5-A-Day’ dietary advice. If successfully
screened, the participant is invited back to complete test
visits 1 and 2. Ineligible participants are thanked for
their time and are offered to join the HNR volunteer
database. Breakfast is provided to all potential volunteers
before the end of the visit.
Pre-test visits 1 and 2
Participants are asked to collect their urine for 24 hours
prior to test visits 1 and 2. Participant randomisation
takes place prior to test visit 1.
Test visit 1
Test visit 1 lasts approximately 5 hours. Any changes to
medication or health status are re-assessed in order to
evaluate whether participants are still suitable to partici-
pate in the study. Height and weight are also measured as
previously described, and BMI is calculated from these
measures. Three waist circumference readings are taken,
measured to the closest 0.1 cm with an anthropometric
measuring tape. Body fat percentage, as well as total body
water, are calculated using a four-point bioelectrical
impedance Tanita BC-418.
Three blood pressure readings are measured in seated
and supine positions before starting the cardiovascular
measurements. Blood pressure is also measured using
the ambulatory blood pressure (ABP) device, which is
programmed to record readings every 15 minutes. In
addition, fasting blood samples are collected during the
Fig. 1 CONSORT flow diagram
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visit to measure the blood markers mentioned in Table 3,
including fasting blood glucose, as well as HbA1c. The fol-
lowing cardiovascular measurements with the following
sequence are performed in a fasting state: carotid intima
media thickness (cIMT), pulse wave analysis (PWA) using
sphygmocor applanation tonometry, laser Doppler ionto-
phoresis (LDI), 12-lead ECG, flow-mediated dilatation
(FMD) and glyceryl trinitrate-induced vasodilation. In
addition, participants provide a single urine sample, and a
member of the study team will carry out a hydration
check using an osmometer and urine dip stick in order to
measure hydration status. Fluid intake is also monitored
during the test visits 1 and 2. At the end of the visit, par-
ticipants complete the IPAQ and FACET questionnaires
and are provided with ‘5-A-Day’ dietary advice. Before
participants leave, they are issued with 6 weeks supply of
capsules. Breakfast/lunch is provided to all participants at
the end of the visit.
Intermediate visit (6 weeks)
The intermediate visit takes place 6 weeks after test visit
1 and lasts approximately 1 hour.
During this visit, a member of the study team as-
sesses any changes to medications or health status to
ensure that participants are still suitable for the study.
Participants return the batch of capsules given during
test visit 1 and are given the next 6 weeks supply of
capsules. Remaining capsules are counted in order to
ensure compliance with the protocol. In addition, fast-
ing blood samples are collected to further monitor
compliance with the intervention by testing vitamins A,
C and E and carotenoid levels. At the end of the visit,
Table 2 Schedule of samples and data collection
Task Pre-screening
(telephone)







Obtain informed consent X
Study eligibility/screening X X
Medical history X
Height, weight and BMI X X X X
Waist circumference X X
Body composition (bioelectrical impedance) X X
Spot urine sample (10 ml) for hydration status assessment including
osmometry and including dipstick
X X
24-hour urine collection X X
Physical activity questionnaire (IPAQ) X X X
Standardised ‘5-A-Day’ advice X X X X
Group randomisation X
FACET (‘5-A-Day’/Lifestyle) Questionnaire X X X X
Blood pressure (standard automated at screening; seated, supine
and ambulatory in TV1 and TV2)
X X X
Pulse wave analysis X X
Carotid intima-media thickness X X
12-lead ECG X X
and GTN-induced dilatation X X
Laser doppler iontophoresis X X
Assess continuance criteria X X X
Blood samples X X X X
Assess concomitant medication X X X X X
Test product dispensed X X
Compliance assessment X X
Tablet count X X
Assess adverse reactions X X
Empty containers collected X X
Collect unused test product X
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participants complete the FACET questionnaire and are
also provided with the ‘5-A-Day’ dietary advice. Break-
fast is provided at the end of the visit.
Test Visit 2
This visit is identical to test visit 1 except that partici-
pants are not provided with more capsules. At the end
of the visit, participants are thanked for their time and
given forms for reimbursement.
Analytic vascular measurements procedures
Carotid intima media thickness (cIMT)
cIMT is performed using a B-mode ultrasound imaging
of the right and left carotid arteries with 7.5 MHz linear
array transducer. In a dark, quiet room, participants are
in a supine position with their head turned 45 o in the
direction opposite to the carotid artery being measured.
Eight longitudinal images of the distal common carotid
arteries (CCA) are obtained, four from each side. On
Table 3 Blood parameters analysed in the National Safety Associates nutritional supplementation trial of fruit and vegetable extracts
and vascular function (NNTV) study






Screening/Safety and Research FBC X X - X
HbA1c X X - X
HDL X X - X
LDL X X - X
Total cholesterol X X - X
Liver function (ALT) X X - X
Creatinine X X - X
Fasting glucose X X - X
Potassium X X - X
Research Oxidized LDL X - X
C-Peptide X - X
Fasting insulin X - X
Apo A1 X - X
Apo A2 X - X
Apo B X - X
Apo E X - X
Cholesterol esters X - X
Oxysterols X - X
Isoprostanes X - X
P-Selectin X - X
E-Selectin X - X
IgM phosphorylcholine X - X
Vitamin A X X X
Vitamin C X X X
Vitamin E X X X
Carotenoids X X X
TMAOd X - X
LPSe X - X
DNA, Metabolomics and other relevant
stored sample analyses
X - X
Urine Xa, b - Xa, b
(1). All screening bloods will be analysed at the Clinical Biochemistry and Immunology Laboratory at Addenbrooke’s Hospital. (2). Participants may be excluded
from the study if screening/safety blood results are deranged. Spot urine collection: a24 hour urine collection: b(3) Additional 15-ml blood samples will be collected
at test visit 1 for future DNA analysis and at test visit 2 for open profile metabolomics. FBC, full blood count; HDL, high density lipoprotein; LDL, low density lipoprotein;
dTMAO, trimethylamine-N-oxide; eLPS, lipopolysaccharide
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completion of the measurements, the images are ana-
lysed by two members of the research team. The out-
come variable is the mean CCA-IMT defined as the
average of four measurements of the far wall IMT of the
right and left CCA.
Pulse wave analysis (PWA)
Aortic augmentation index (AIx) is derived from the right
wrist (radial pulse) using the SphygmoCor Vx version 7.01
(AtCor Medical, Sydney, Australia). The SphygmoCor
device provides a quality index (QI), which represents
reproducibility of the waveform, and any recordings with
a QI < 80 are excluded. Because the AIx changes with
heart rate, the software adjusts this value for a heart rate
of 75 beats per minute (AIx@HR75).
Laser Doppler imaging following iontophoresis
Vascular changes related to microcirculatory flow and
endothelial function are identified using the laser doppler
imaging (LDI) technique (Moor Instruments, UK) with
iontophoresis of acetylcholine (Ach) and sodium nitroprus-
side (SNP). The room temperature is set at 22 to 23 °C,
and the measurement is taken from the participant’s right
arm while he/she is in a seated position. Each drug is ad-
ministered at increasing currents of 0 μA, 40 μA, 60 μA
and 100 μA for 5, 10, 30 and 60 seconds, respectively. Cu-
mulative dose response curves are analysed automatically
by the built-in software (MoorVMS-PC software).
Electrocardiogram (ECG)
A 12-lead ECG is recorded in each participant with a 12-
channel ECG machine (GEM MED, GEM heart one+,
Cambridge, UK) on a paper with a speed of 25 mm/sec
and 10 mm/mv standardisation. ECG waveforms are also
saved in the gem heart viewer software (GEM MED, Cam-
bridge, UK) for further examination and analysis if
needed. ECG is performed once during test visits 1 and 2.
Flow-mediated dilatation and induced vasodilation using
glycerol trinitrate
FMD is assessed in the brachial artery by high-resolution
ultrasound and computerised edge detection system
(FMD studio, Quipu srl, Pisa, Italy). All FMD measure-
ments are performed while the participants are in a supine
position with their right arm extended and in a quiet,
darkened room kept at a relatively constant temperature
(22 to 23 °C) to minimise the possible negative effect of
environmental and physiological influences. The blood
pressure cuff is placed on the right forearm, 1 to 2 cm
distal to the elbow crease, and an ultrasound probe holder
is used to hold the probe stable on the antecubital fossa.
The brachial artery is continuously imaged using a 7.5-
MHz probe in B-mode (Accuson X300, Siemens UK; with
a VF 8-3 probe) at a depth of 3 cm. The brachial artery
diameter is measured on acquired frames using Quipu
software (Quipu srl, Pisa, Italy). Baseline brachial artery
images and blood-flow velocity prior to occlusion cuff in-
flation are recorded for 1 minute. The occlusion cuff
is then inflated to 200 mmHg for 5 minutes and
released, thereby inducing reactive hyperaemia and
endothelium-dependent vasorelaxation, which is moni-
tored for 4 minutes. Following a 10-minute recovery
period, endothelium independent dilation is monitored
over a 5-minute period after sublingual administration of
300 μg glycerol trinitrate (GTN) spray. Flow-mediated
and GTN-induced dilatation of the brachial artery are
expressed as maximum percent dilatation following cuff
deflation and GTN administration, respectively.
Side effects and safety assessments
All participants are provided with a booklet where they
can record any potential side effects. In case they develop
severe side effects, they are advised to stop the supple-
mentation and will be excluded from the study. All serious
and non-serious adverse events and/or reactions involving
capsules supplementation are logged by a member of the
study team in a password protected database. In addition,
any abnormal results of clinical importance detected dur-
ing the course of the study (screening, test visits 1 and 2)
will be reported by the HNR clinical team to the partici-
pant’s general practitioner (GP).
Biological sampling
A 15-ml blood sample will be collected from each partici-
pant at the screening visit and approximately 40 ml will
be collected during test visits 1 and 2. Table 3 outlines the
blood parameters that are analysed in each study visit.
Participants collect-24 hour urine samples, which will
be used to investigate the bioavailability of key polyphenol
compounds present in the capsules. In addition, hydration
status is measured using urine osmolality and urine dip
stick from both the urine collected over 24 hours and
from the single urine sample collected during test visits 1
and 2.
Data analysis
A consort flowchart of enrolled participants will be pro-
vided, and the demographic characteristics recorded at the
time of randomisation will also be described. Descriptive
analysis will be conducted for all baseline variables to
compare participants in both study groups. Results will be
reported as means and standard deviations for continuous
variables and frequencies with percentages for categorical
variables. Two group comparisons for changes in primary
and secondary outcome measures following 12 weeks of
intervention will be made, assuming similar levels of
variance between the two treatment groups and using
two-tailed t-tests for normally distributed data. Paired t-
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tests will be used to assess within-group changes in study
outcomes. Multiple linear regression models will be used
to assess whether changes from baseline to 12 weeks were
significant between the study groups. Regression analysis
will be conducted, with adjustment for potential baseline
confounding variables. Additionally, a sensitivity analysis
will be performed, exploring variation in the standard de-
viation between the differences of the mean change in
cIMT measurements. Exploratory within-group changes
will also be assessed for each outcome measure.
Discussion
This study was designed to test the hypothesis that sup-
plementation with capsules containing a combination of
fruit and vegetables, in addition to dietary advice to con-
sume five portions of fruit and vegetables daily, will sig-
nificantly modulate biomarkers of vascular and metabolic
function in overweight and obese adults, compared with a
control group receiving identical dietary advice to con-
sume ‘5-A-Day’ and placebo capsules. The particular
population was chosen for this study as overweight and
obese individuals have increased cytokines free fatty acids
and inflammation markers. These increases can lead to
early endothelial dysfunction due to increased inflamma-
tion and other mechanisms associated with overweight
and obesity.
This study was powered with cIMT as a primary out-
come. However, as cIMT is a dynamic but structural meas-
urement, a number of functional measurements, including
those assessing vascular endothelium and smooth muscle
tone, as well as both factors together, form part of the panel
of outcome measures used in this mechanistic trial. These
measures were designed to provide novel insights into
vascular function pathways and the prediction of cardiovas-
cular risk. In addition to vascular measurements, waist
circumference, blood pressure and hydration status are
expected to provide complementary information.
In particular, this explanatory trial also incorporates po-
tential novel biomarkers such as trimethylamine-N-oxide
(TMAO) and lipopolysaccharide (LPS). Polyphenolic
compounds have recently been found to modulate TMAO
[11, 12]. Evaluating the ability of the NNTV study inter-
ventions on TMAO concentrations might be useful to
understand if the polyphenolic fraction of this extract acts
as a gut microbial modulator, reducing cardiovascular
disease risk through the control of trimethylamine
production.
Lipopolysaccharide (LPS), also known as endotoxin, is a
component of the cell wall of gram-negative bacteria that
may normally reside in the colon of humans. Additionally,
polyphenolic compounds have been attributed to modula-
tion of the gut microbiome, through mechanisms involving
their bacteriostatic activity and the inhibition of microbial
fermentation [11, 12]. Assessing the ability of the fruit and
vegetable extract to change levels of LPS can help explain
if the polyphenolic fraction of this extract acts as a gut mi-
crobial modulator, reducing future disease risk through the
control of endotoxaemia.
Trial Status
This clinical trial was registered in February 2014. At the
time of manuscript submission, the enrolment of volun-
teers was ongoing. The estimated study completion date is
December 2015. Please refer to this study by its ISRCTN
identifier: ISRCTN14315618.
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